This is a preview of subscription content, log in via an institution to check access.
References
Oral mucositis: challenging the priorities of cancer therapy [report]. New York: Datamonitor, 2003
Amgen. FDA approves Kepivance for severe oral mucositis in cancer patients undergoing bone marrow transplant; pivotal phase 3 study published in this week’s New England Journal of Medicine. Media release: 15 Dec 2004
Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351 (25): 2590–8
Aesgen. SaforisTM: treating the patient not just the disease. Company communication: 15 Oct 2003 [online]. Available from: URL: http://www.aesgen.net [Accessed 17 May 2005]
CuraGen. CuraGen announces single-dose phase I data on velafermin (CG 53135) for prevention of oral mucositis. Media release: 17 May 2005
Schuster MW, Shore TB, Greenberg J, et al. Phase I Trial of CG53135-05 to Prevent Mucositis in Patients Undergoing High-dose Chemotherapy (HDCT) and Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) [abstract 6656]. 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL).
Rights and permissions
About this article
Cite this article
Overcoming Oral Mucositis. Pharmaceutical & Diagnostic Innovation 3, 11–13 (2005). https://doi.org/10.1007/BF03256963
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03256963